Dynatronics (DYNT) AI Stock Analysis

• Market Cap: $934.52K
• Dividend Yield: N/A
• Average Volume (3M): 5.62K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: -15.39%
• EPS Growth: 56.69%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): -0.56
• Shares Outstanding: 10,619,543
• 10 Day Avg. Volume: 6,468
• 30 Day Avg. Volume: 5,619
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 15.49
• Enterprise Value/Revenue: 0.51
• Enterprise Value/Gross Profit: 2.26
• Enterprise Value/Ebitda: -9.44
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

Dynatronics receives a low overall stock score due to financial performance challenges and valuation concerns. The company's declining revenues, unprofitable status, and inconsistent cash flows weigh heavily on its prospects. Technical analysis offers a neutral view but does not offset the significant financial and valuation issues.

Positive Factors

Management Quality

The appointment of Ryan Staats as COO, with extensive industry experience, strengthens leadership and could enhance operational efficiency and compliance.

Product Diversification

A broad product portfolio in medical devices and rehabilitation equipment positions Dynatronics to capture diverse market opportunities and mitigate single-product risks.

Strategic Partnerships

Strategic partnerships can expand market reach and enhance product offerings, contributing to revenue growth and competitive positioning over time.

Negative Factors

Declining Revenue

Consistent revenue decline signals challenges in market demand or competitive positioning, impacting long-term growth and financial health.

Profitability Challenges

Ongoing profitability issues, indicated by negative EBIT and net income, suggest operational inefficiencies and hinder sustainable financial performance.

Cash Flow Inconsistencies

Inconsistent cash flows limit the company's ability to invest in growth opportunities and maintain financial stability, posing long-term operational risks.

Dynatronics Business Overview & Revenue Model

Company Description

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. Its orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. The company provides therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. It also offers power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, and other related equipment. In addition, the company provides clinical supplies, including exercise bands and tubings, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals, as well as online. It also exports its products to approximately 30 countries. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

How the Company Makes Money

Dynatronics makes money through the sale of its medical devices and rehabilitation equipment to healthcare providers such as hospitals, clinics, and individual practitioners. The company generates revenue by manufacturing and distributing a wide array of products that are critical in therapeutic and rehabilitation settings. Key revenue streams include direct sales to healthcare facilities and practitioners, as well as through partnerships with distributors who expand the company's reach in various markets. Additionally, Dynatronics may engage in strategic partnerships or collaborations that enhance its product offerings and market presence, contributing to its earnings.

Dynatronics Financial Statement Overview

Summary

Dynatronics faces significant challenges in revenue growth and profitability, with declining revenues and a decrease in gross profit margin. The balance sheet maintains a moderate debt-to-equity ratio, but declining stockholders' equity raises concerns. Cash flow inconsistencies further highlight the struggle to sustain positive cash flows, necessitating strategic improvements.

Income Statement

Dynatronics has experienced declining revenues over the past years, with the TTM revenue showing a significant decrease from previous periods. The gross profit margin has also decreased, indicating potential cost management issues. The company continues to report negative EBIT and net income, reflecting ongoing profitability challenges. Despite these issues, the company has managed to improve its EBITDA margin slightly in recent periods.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced capital structure. However, stockholders' equity has been declining, which could signal eroding shareholder value. The equity ratio remains stable, yet there's a noticeable decrease in total assets over recent years, which may impact the company's growth potential.

Cash Flow

The cash flow statement reveals inconsistent operating cash flows, with the latest TTM showing a slight positive shift. Despite this, free cash flow remains low, reflecting limited cash generation after capital expenditures. The company has managed to slightly improve its cash position compared to the previous year, but challenges in sustaining positive cash flows persist.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.43M	32.53M	40.61M	44.34M	47.80M	53.41M
Gross Profit	6.41M	7.63M	10.15M	10.67M	12.89M	15.10M
EBITDA	-1.53M	-976.01K	-3.50M	-2.42M	3.81M	-1.26M
Net Income	-3.02M	-2.70M	-5.66M	-4.73M	1.21M	-4.32M
Balance Sheet
Total Assets	23.45M	25.94M	30.06M	35.43M	39.14M	27.57M
Cash, Cash Equivalents and Short-Term Investments	174.09K	483.92K	398.80K	550.11K	6.10M	2.32M
Total Debt	5.81M	6.69M	5.65M	3.84M	5.08M	1.01M
Total Liabilities	11.43M	11.78M	13.21M	13.73M	13.63M	7.68M
Stockholders Equity	12.02M	14.16M	16.86M	21.70M	25.51M	19.90M
Cash Flow
Free Cash Flow	428.51K	-1.85M	185.15K	-5.20M	236.13K	2.80M
Operating Cash Flow	461.10K	-1.61M	372.00K	-4.88M	383.00K	3.09M
Investing Cash Flow	-32.31K	-243.29K	-187.00K	-319.00K	1.53M	-292.36K
Financing Cash Flow	-799.63K	1.84M	-332.71K	-350.00K	2.02M	-737.08K

Dynatronics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYNT, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 52.41 is Neutral, neither overbought nor oversold. The STOCH value of 42.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYNT.

Dynatronics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AXGN	69 Neutral	$773.01M	―	-4.48%	―	17.17%	72.68%
XTNT	52 Neutral	$80.94M	―	-9.80%	―	15.16%	-39.18%
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
DYNT	49 Neutral	$934.52K	―	-21.05%	―	-15.39%	56.69%
NURO	45 Neutral		―		―	-48.61%	32.18%
NUWE	44 Neutral	$3.80M	―	-440.77%	―	-7.72%	99.54%
HIND	37 Underperform	$5.08M	―	-101.49%	―	-19.81%	93.32%

Dynatronics Corporate Events

Dynatronics Appoints Ryan Staats as New COO

On May 9, 2025, Dynatronics announced the appointment of Ryan Staats as its new Chief Operating Officer. Mr. Staats, who has been with the company since 2022, previously served as Vice President of Operations and Supply Chain. With over 17 years of experience in the medical device industry, including roles at SeaSpine, Inc. and Integra Lifesciences Holdings Corp., Staats brings extensive expertise in supply chain management and regulatory compliance to his new role.